Recent Updates — POM

POMDOCTOR Limited has commenced the termination of its American Depositary Receipt (ADR) program and related deposit agreement, following prior board and shareholder approval. The ADR Program is expected to terminate prior to market open on October 21, 2026, at which point ADSs will be mandatorily cancelled and exchanged for Class A ordinary shares. Simultaneously, the company will effect a share consolidation where every ten ordinary shares of each class are consolidated into one. Consequently, holders of ten ADSs will receive three post-consolidation Class A ordinary shares. The company plans to list its Class A ordinary shares on Nasdaq under the symbol "POM" starting October 21, 2026. POMDOCTOR Limited operates in the healthcare and medical technology sector.

The Nasdaq Stock Market notified POMDOCTOR Limited that its American depositary shares closed below $1.00 per share for 30 consecutive business days, triggering a delisting determination from the Listing Qualifications Department. The company is ineligible for the standard 180-day compliance period because it executed a 1-for-18 reverse stock split on June 22, 2026. Securities are scheduled to be suspended from trading on October 15, 2026, unless an appeal is filed by the October 13 deadline. The company intends to request a hearing before a Nasdaq Hearings Panel to present a plan for regaining compliance, which will stay the suspension pending the panel's decision. POMDOCTOR Limited operates in the digital healthcare industry, focusing on AI-enabled solutions and predictive capabilities.

On September 30, 2026, POMDOCTOR Limited shareholders approved the termination of its American Depositary Receipt program and a ten-for-one share consolidation. The ADR termination and direct listing on Nasdaq will occur simultaneously with the consolidation, which increases par value from US$0.0001 to US$0.001 per share. The company also amended its authorized share capital from 500 million to 50 million shares while maintaining a total par value of US$50,000. Fractional shares resulting from the consolidation will be rounded up to the nearest whole number. POMDOCTOR Limited operates in the healthcare technology industry, providing digital health solutions.